The PSMA (prostate-specific membrane antigen) known as glutamate carboxypeptidase II (GCP-II) is a transmembrane, 750 amino acid, type II glycoprotein, which is expressed virtually by almost all primary prostate cancer (PCa) and metastatic disease as well [4]. Here, FOLH1 is linked to posterior cortical atrophy.